Shares jumped 6.6% in a single day to close at $28.98, rising against a weaker market (the Nasdaq and S&P both closed lo

Consensus target

28.7

Key points

• Shares jumped 6.6% in a single day to close at $28.98, rising against a weaker market (the Nasdaq and S&P both closed lower) on heavier volume.
• Technicals: the stock is back above its 20-day ($25.39), 50-day ($24.96) and 100-day ($23.61) moving averages, but still 17.8% below the 200-day ($33.85). Benzinga called it a 'repair rally'.
• The main catalyst was a rumour of a possible wider partnership with Novo Nordisk (not confirmed first-hand by Bloomberg or Reuters, and no official announcement). HIMS and Novo resumed their distribution partnership for branded semaglutide in March 2026.
• A new channel for speculation: HIMS perpetual contracts have gone live on crypto exchanges, amplifying short-term swings in both directions. The CME's CEO has publicly warned about the risks of high leverage.
• Tomorrow's annual shareholder meeting (11 Jun): watch the votes on CEO Dudum's pay package (a pay ratio of 272:1) and the board nomination of former DoorDash CMO Kofi Amoo-Gottfried.
• The consensus price target is $28.70 (13 banks). The shares are now roughly at consensus, so upside has narrowed.

Price

28.98